Free Trial
LON:HEMO

Hemogenyx Pharmaceuticals (HEMO) Share Price, News & Analysis

Hemogenyx Pharmaceuticals logo
GBX 178.30 +1.80 (+1.02%)
As of 11:18 AM Eastern

About Hemogenyx Pharmaceuticals Stock (LON:HEMO)

Key Stats

Today's Range
177
179
50-Day Range
167.25
198
52-Week Range
160
1,200
Volume
15,508 shs
Average Volume
30,442 shs
Market Capitalization
£6.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.

Receive HEMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemogenyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HEMO Stock News Headlines

Trump’s treachery
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Hemogenyx Pharmaceuticals Announces Key Corporate Changes
See More Headlines

HEMO Stock Analysis - Frequently Asked Questions

Hemogenyx Pharmaceuticals' stock was trading at GBX 402 at the beginning of the year. Since then, HEMO stock has decreased by 55.6% and is now trading at GBX 178.30.
View the best growth stocks for 2025 here
.

Hemogenyx Pharmaceuticals Plc (LON:HEMO) issued its quarterly earnings data on Monday, April, 28th. The company reported ($181.10) earnings per share (EPS) for the quarter.

Shares of HEMO stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hemogenyx Pharmaceuticals investors own include 4D pharma (DDDD), genedrive (GDR), International Consolidated Airlines Group (IAG), Active Energy Group (AEG), B&M European Value Retail (BME), BP (BP) and Coats Group (COA).

Company Calendar

Last Earnings
4/28/2025
Today
5/23/2025

Industry, Sector and Symbol

Stock Exchange
LON
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
LON:HEMO
Previous Symbol
LON:SILF
CIK
N/A
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
£-6,890.55
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
GBX 87.19 per share
Price / Cash Flow
2.05
Book Value
GBX 0.25 per share
Price / Book
723.74

Miscellaneous

Free Float
N/A
Market Cap
£6.36 million
Optionable
Not Optionable
Beta
3.14
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (LON:HEMO) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners